Chengdu Zenitar Biomedical Technology Co., Ltd

Quick facts

Phase 3 pipeline

• Purinostat Mesylate for Injection · Oncology
  Purinostat Mesylate for Injection is a histone deacetylase inhibitor that works by blocking the activity of histone deacetylases, leading to the accumulation of acetylated histones and changes in gene expression.
• Selinexor Tablets · Oncology
  Selinexor is a selective inhibitor of nuclear export (SINE) that blocks XPO1/CRM1, preventing the export of tumor suppressor proteins from the nucleus and leading to their accumulation and activation.

Phase 2 pipeline

• Extended Phase Dose Group
• Flonoltinib Maleate · Oncology
  Flonoltinib maleate is a tyrosine kinase inhibitor that targets the BCR-ABL1 protein.
• The high-dose group of ZL-82 tablets
• The low-dose group of ZL-82 tablets

Phase 1 pipeline

• Flonoltinib Maleate Tablets
• flunotinib · Other
• ZL-82
• ZL-85FA tablets

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Chengdu Zenitar Biomedical Technology Co., Ltd portfolio CI brief
• Chengdu Zenitar Biomedical Technology Co., Ltd pipeline updates RSS